Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate Passes Bill on Cheaper Drugs (Phillipines)

This article was originally published in PharmAsia News

Executive Summary

The Quality Affordable Medicines Act was among the eight bills passed by the Philippines Senate on Nov. 5. Proposed by Sen. Mar Roxas, the bill will make patent laws more liberal in an effort to reduce prescription drug prices. Additionally, the bill will bolster the Generics Drug Act and widen parallel imports of common medicines by the government. The bill is now being considered by the House. "The more time the House and the Senate have to discuss and reconcile the versions of the bill, the more responsive the bill could be [to] our countrymen's health needs, Roxas notes." (Click here for more

You may also be interested in...



Drug Access Act Bringing Down Prices In The Philippines

The Philippines' Universally Accessible Cheaper and Quality Medicine Act of 2008 will bring down local drug prices in the country by promoting a level playing field and free competition, the Philippine Chamber of the Pharmaceutical Industry said at a generics summit in Pasay City

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel